Baird Starts iTeos Therapeutics (ITOS) at Outperform

October 7, 2020 4:09 PM EDT
Get Alerts ITOS Hot Sheet
Price: $27.46 +0.44%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 13 | New: 22
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Baird analyst Michael Ulz initiates coverage on iTeos Therapeutics (NASDAQ: ITOS) with a Outperform rating and a price target of $45.00.

The analyst commented, "iTeos is focused on developing next-generation, immuno-oncology treatments, with two assets in the clinic against validated targets involved in immune suppression. Lead assets, EOS-850 (A2AR) and EOS-448 (TIGIT) have shown differentiated profiles preclinically, while EOS-850 has demonstrated promising early clinical activity. This, combined with an experienced management team and catalysts for both programs expected in 1H21 (potentially AACR or ASCO), provides multiple opportunities for upside. Hence, we are initiating coverage with an Outperform rating and $45 price target."

For an analyst ratings summary and ratings history on iTeos Therapeutics click here. For more ratings news on iTeos Therapeutics click here.

Shares of iTeos Therapeutics closed at $21.59 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Robert W Baird